The purpose of this study is to measure the body's absorption and processing of the study drug, the study drug's effect on the body, safety, and tolerability with LY4268989 (MORF-57) in healthy participants, including Japanese and Chinese participants
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4268989 (Cohort 1) and (Cohort 5)
Timeframe: Day 1 to Day 17
PK: Area Under the Concentration Curve (AUC) of LY4268989 (Cohort 1) and (Cohort 5)
Timeframe: Day 1 to Day 17
Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (Cohort 1), (Cohort 3), and (Cohort 5)
Timeframe: Baseline to Study Completion (Up to Day 17)
Number of Participants with TEAEs and SAEs (Cohort 4)
Timeframe: Baseline to Study Completion (Up to Period 4, Day 4)
PK: Cmax of LY4268989 (Cohort 2)
Timeframe: Day 1 to Day 13
PK: AUC of LY4268989 (Cohort 2)
Timeframe: Day 1 to Day 13
PK: AUC of Midazolam and 1'-Hydroxymidazolam (Cohort 3)
Timeframe: Day 1 to Day 17
PK: AUC of Midazolam and 1'-Hydroxymidazolam (Cohort 8)
Timeframe: Day 3 and Day 11
PK: Cmax of Midazolam and 1'-Hydroxymidazolam (Cohort 3)
Timeframe: Day 1 to Day 17
PK: Cmax of Midazolam and 1'-Hydroxymidazolam (Cohort 8)
Timeframe: Day 3 to Day 11
PK: Cmax of LY4268989 (Cohort 6)
Timeframe: Day 1 to Day 7
PK: AUC of LY4268989 (Cohort 6)
Timeframe: Day 1 to Day 7
PK: Cmax of LY4268989 (Cohort 7)
Timeframe: Day 1 to Day 12
PK: AUC of LY4268989 (Cohort 7)
Timeframe: Day 1 to Day 12